JMP Securities Reiterates “Market Outperform” Rating for Jasper Therapeutics (NASDAQ:JSPR)

JMP Securities restated their market outperform rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research report report published on Monday morning,Benzinga reports. JMP Securities currently has a $70.00 price objective on the stock.

A number of other analysts also recently issued reports on JSPR. BMO Capital Markets assumed coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 target price for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $68.00 price objective on shares of Jasper Therapeutics in a research report on Monday, December 23rd. Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $65.00 price target on shares of Jasper Therapeutics in a research report on Thursday, October 24th. Ten research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $73.38.

Jasper Therapeutics Trading Up 8.3 %

JSPR stock opened at $20.87 on Monday. The stock has a 50-day moving average price of $22.05 and a two-hundred day moving average price of $20.49. The company has a market cap of $313.07 million, a PE ratio of -4.40 and a beta of 2.18. Jasper Therapeutics has a 12-month low of $6.61 and a 12-month high of $31.01.

Institutional Trading of Jasper Therapeutics

Large investors have recently modified their holdings of the business. Samsara BioCapital LLC boosted its holdings in Jasper Therapeutics by 11.4% in the third quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock valued at $10,997,000 after purchasing an additional 59,642 shares during the last quarter. Braidwell LP purchased a new position in shares of Jasper Therapeutics during the 3rd quarter valued at approximately $9,091,000. Ally Bridge Group NY LLC grew its position in shares of Jasper Therapeutics by 82.7% during the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after buying an additional 180,852 shares in the last quarter. State Street Corp increased its stake in shares of Jasper Therapeutics by 12.3% in the third quarter. State Street Corp now owns 214,883 shares of the company’s stock worth $4,042,000 after buying an additional 23,564 shares during the last quarter. Finally, Fernwood Investment Management LLC raised its holdings in Jasper Therapeutics by 6.9% in the third quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company’s stock valued at $995,000 after acquiring an additional 3,427 shares in the last quarter. 79.85% of the stock is currently owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.